熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
三生制藥,3SBio,
沈陽(yáng)三生制藥有限責(zé)任公司成立于1993年,是集生物藥品的研發(fā)、生產(chǎn)和銷售一體化的高新技術(shù)企業(yè)。公司開發(fā)重組或基因工程蛋白類藥物,以滿足臨床治療腎臟病、腫瘤、腫瘤支持治療、以及其他炎癥和傳染類疾病的市場(chǎng)需求。主要產(chǎn)品包括重組人紅細(xì)胞生成素(益比奧)、重組人血小板生成素(特比澳)、重組人干擾素α2a(因特芬)和重組人白細(xì)胞介素-2(英路因)。其中特比澳是公司自主研發(fā)的國(guó)家一類新藥,2006年1月產(chǎn)品上市銷售。 公司的生產(chǎn)基地位于沈陽(yáng)經(jīng)濟(jì)技術(shù)開發(fā)區(qū),生產(chǎn)車間面積3000平方米,通過(guò)了國(guó)家GMP認(rèn)證。生產(chǎn)基地大批量生產(chǎn)益比奧、特比澳、因特芬和英路因等四種產(chǎn)品,供應(yīng)臨床應(yīng)用和商業(yè)需求。
A message from Dr. Lou Jing
Since the establishment in 1993, we have successfully conducted the research, development and industrialization of four genetically engineered, protein-based products, and a few new product candidates are in the R&D or process of registration stages; we have established a quality control system in accordance with SFDA regulations and our manufacturing facilities fully comply with the Chinese GMP Guidelines which could produce for both clinical and commercial purposes; European Pharmacopoeia 2002 version on quality control has been implemented by us since 2004.
We maintain our sales and marketing forces in 31 provinces and major cities and continually expanding our targeted market through our 461 marketing & sales professionals and approximately 110 distributors, and have gained big market share in both volume and sales. The strong financial profile with a track record of growth and profitability is a good evidence to show that our company has entered into a stage of rapid development.
We should base on all of the above achievements and to accomplish further objectives. We will insist on the development direction of biotechnologies and carry on our specialization to develop new technologies and products with independent intellectual property.
Our goal is to become the leader in the research, development, manufacture and commercialization of protein-based therapeutics in China and continue to advance our drugs into international markets.
We believe that our leading position in the market, diverse portfolio of marketed products, proven research and development capabilities, nationwide sales and marketing network; high quality proprietary manufacturing processes and experienced and market-oriented management team will enable us to achieve our goals.